 |
|
Risk assessment plays key role in long-term treatment of breast cancer
August 13, 2008HOUSTON - Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.
The 2,838 women studied were diagnosed with Stage I through III breast cancers and had been treated with adjuvant systemic therapy (AST), such as chemotherapy and or tamoxifen between 1985 and 2001, and were in the M. D. Anderson Tumor Registry. The patients in the study were five years from the start of their AST and were cancer-free. The researchers calculated the residual or remaining risk of recurrence from the benchmark of five years from the start of AST and determined the factors that contributed to a higher residual risk of recurrence.
"Understandably, one of the most common questions posed by breast cancer survivors is 'What are the chances of it coming back?'," said the study's lead author, Abenaa Brewster, M.D., assistant professor in M. D. Anderson's Department of Clinical Cancer Prevention. "Now we can tell some women within a certain percentage their future risk of recurrence and clinicians may be able to make more informed decisions regarding prescription of extended adjuvant endocrine therapy."
Data analysis revealed that 89 percent of the study populations did not experience a recurrence at five years (approximately 10 years after a woman's initial diagnosis), and 80 percent did not experience a recurrence at 10 years (approximately 15 years after diagnosis).
Brewster commented that, while reassuring for most of the five-year survivors, the percentage of the population who had a recurrence is significant to oncologists.
"The magnitude of risk of recurrence should indicate a need for us to consider extended endocrine treatment for eligible women to further lower their risks," said Brewster. Additionally, the study did not include women who received adjuvant systemic therapy with trastuzamab or five years of aromatase inhibitor treatment and therefore the residual risk of recurrence among those groups of patients could not be determined.
Median follow-up time for women in the study was 28 months. During that time, 216 of the women experienced a recurrence. The five-year residual risks of recurrence for patients with Stage I, II and III cancers were 7 percent, 11 percent and 13 percent respectively. Patients with Stage II or III versus Stage I disease and patients with grade I versus grade III tumors had a higher risk of late recurrence. Patients who had estrogen receptor-positive tumors who received adjuvant endocrine therapy also had a higher risk of recurrence than those with hormone receptor-negative tumors but the difference was not found to meet statistical significance.
The study also indicated a need for the continued development of risk-reduction strategies for pre-menopausal breast cancer survivors because of lack of available therapies in this younger age group. Currently, extended adjuvant endocrine therapy with letrozole (Femara) is available only for post-menopausal patients with hormone receptor positive tumors who have completed five years of tamoxifen therapy.
University of Texas M. D. Anderson Cancer Center
Data analysis revealed that 89 percent of the study populations did not experience a recurrence at five years (approximately 10 years after a woman's initial diagnosis), and 80 percent did not experience a recurrence at 10 years (approximately 15 years after diagnosis).
Brewster commented that, while reassuring for most of the five-year survivors, the percentage of the population who had a recurrence is significant to oncologists.
"The magnitude of risk of recurrence should indicate a need for us to consider extended endocrine treatment for eligible women to further lower their risks," said Brewster. Additionally, the study did not include women who received adjuvant systemic therapy with trastuzamab or five years of aromatase inhibitor treatment and therefore the residual risk of recurrence among those groups of patients could not be determined.
Median follow-up time for women in the study was 28 months. During that time, 216 of the women experienced a recurrence. The five-year residual risks of recurrence for patients with Stage I, II and III cancers were 7 percent, 11 percent and 13 percent respectively. Patients with Stage II or III versus Stage I disease and patients with grade I versus grade III tumors had a higher risk of late recurrence. Patients who had estrogen receptor-positive tumors who received adjuvant endocrine therapy also had a higher risk of recurrence than those with hormone receptor-negative tumors but the difference was not found to meet statistical significance.
The study also indicated a need for the continued development of risk-reduction strategies for pre-menopausal breast cancer survivors because of lack of available therapies in this younger age group. Currently, extended adjuvant endocrine therapy with letrozole (Femara) is available only for post-menopausal patients with hormone receptor positive tumors who have completed five years of tamoxifen therapy.
University of Texas M. D. Anderson Cancer Center
Breast Cancer Current Events and Breast Cancer News RSSStudy identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
UNC researchers find clue to stopping breast-cancer metastasis
If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction.
Fear, misconceptions about screenings keep many African-Americans from getting mammograms
Training physicians and caregivers to improve cultural sensitivity and communication with economically disadvantaged African-American patients could influence these women to get mammograms that could save their lives.
New technology could revolutionize breast cancer screening
The world's first radar breast imaging system developed at Bristol University that could revolutionise the way women are scanned for breast cancer, is being trialled at North Bristol NHS Trust (NBT).
Battling bacteria in the blood: Researchers tackle deadly infections
It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.
Mayo Clinic Study Finds Risk Assessment Tool Not Reliable Predictor for Some Women at High Risk of Breast Cancer
A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology.
Migraines associated with lower risk of breast cancer
Women who suffer from migraines may take at least some comfort in a recent, first-of-its-kind study that suggests a history of such headaches is associated with a significantly lower risk of breast cancer.
Folic acid, B vitamins do not appear to affect cancer risk
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA.
Healthy bones program reduces hip fractures by 37 percent
Proactive measures can reduce hip fracture rates by an average of 37.2 percent -- and as much as 50 percent -- among those at risk, according to a study conducted by Kaiser Permanente Southern California. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal.
More Breast Cancer Current Events and Breast Cancer News Articles
 | Breast Cancer Husband : How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond by Marc Silver A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time. When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give... |
 | Chicken Soup for the Breast Cancer Survivor's Soul: Stories to Inspire, Support and Heal (Chicken Soup for the Soul) by Jack Canfield, Mark Victor Hansen, Mary Olsen Kelly Your support group in a book, filled with boundless strength and profound hope - until the fight is won. Along with the shock, fear and loss many women face upon a breast cancer diagnosis comes unexpected strength, wisdom, and strong networks of sharing, support and healing. In Chicken Soup for the Breast Cancer Survivor's Soul, survivors and their family members talk openly about how difficult... |
 | Choices in Breast Cancer Treatment: Medical Specialists and Cancer Survivors Tell You What You Need to Know (A Johns Hopkins Press Health Book) A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions.Within these pages is a team of private consultants -- including surgeons, medical... |
 | The Breast Cancer Survivor's Fitness Plan (Harvard Medical School Guides) by Carolyn M. Kaelin, Francesca Coltrera, Josie Gardiner, Joy Prouty The only breast cancer recovery program designed by a Harvard doctor and survivor and approved by the American Council on Exercise (ACE) Feel healthy again. Regain control of your life. Exciting new research reveals that regular exercise can reduce the chance of breast cancer recurrence and extend your life. Exercise can also help you recover energy, strength, and flexibility diminished by... |
 | Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second... |
 | What Your Doctor May Not Tell You About(TM): Breast Cancer: How Hormone Balance Can Help Save Your Life (What Your Doctor May Not Tell You About...) by John R. Lee, David Zava, Virginia Hopkins An informative and absorbing read for both medical practitioners and their patients, What Your Doctor May Not Tell You About Breast Cancer takes aim at "the breast cancer industry" with a barrage of thought-provoking ammunition. The book is equal parts criticism and suggestion. Current health treatments, including HRT, receive serious condemnation, and authors John Lee and David Zava carefully... |
 | Breast Cancer: Real Questions, Real Answers by David Chan Breast Cancer: Real Questions, Real Answers is an outgrowth of Dr. David Chan's more than 20 years in private oncology practice. Inspired by his patients—who courageously face their illness but often feel fearful, confused about their options, and full of questions—Dr. Chan's book is uniquely structured as a Question and Answer between patient and doctor. It provides readers with an easily... |
 | I Am Not My Breast Cancer: Women Talk Openly About Love and Sex, Hair Loss and Weight Gain, Mothers and Daughters, and Being a Woman with Breast Cancer by Ruth Peltason I Am Not My Breast Cancer gathers the warm, loving, frank, and informed voices of more than eight hundred women—from every state in the nation and from continents as far away as Australia and Africa—who reveal their fears, trade advice, share experiences, and express their deepest, most intimate concerns. Essential reading for any woman with this diagnosis, it offers the companionship of... |
 | The Breast Cancer Prevention Diet: The Powerful Foods, Supplements, and Drugs That Can Save Your Life by Dr. Bob Arnot "From one of the most visible and highly respected figures in medical journalism comes a book that can literally save lives. During the past several years, doctors at leading institutions across the nation have been investigating the relationship between breast cancer and diet. The recent flood of medical studies confirm that what a woman eats can have a dramatic impact on whether or not... |
 | Living Through Breast Cancer - PB by Carolyn M. Kaelin Winner of two prestigious American Medical Writers Association awards A compassionate guide to surviving breast cancer from a doctor who has experienced it from both sides of the stethoscope In addition to being a leading national breast cancer expert and a highly respected cancer surgeon, Dr. Carolyn Kaelin also is a breast cancer survivor. In Living Through Breast Cancer she draws upon her... |
| © 2008 BrightSurf.com |